Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Accured Expenses for 10 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 185.7% to $13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.5 million through Dec 2025, up 479.82% year-over-year, with the annual reading at $48.5 million for FY2025, 479.82% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $13.9 million at Akebia Therapeutics, down from $15.8 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $30.8 million in Q3 2021, with the low at -$37.2 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$1.7 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses plummeted 440.04% in 2023, then skyrocketed 2984.2% in 2025.
  • Over 5 years, Change in Accured Expenses stood at -$37.2 million in 2021, then soared by 55.7% to -$16.5 million in 2022, then skyrocketed by 122.55% to $3.7 million in 2023, then surged by 31.26% to $4.9 million in 2024, then soared by 185.7% to $13.9 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $13.9 million, $15.8 million, and $16.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.